Glucocorticoids in the treatment of patients with primary focal segmental glomerulosclerosis and moderate proteinuria
| Autor: | Pingyan Shen, Jingyuan Xie, Li Lin, Xiao Li, Nan Chen, Xiaoxia Pan, Jian-Ni Huang, Hong Ren |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Nephrology medicine.medical_specialty Time Factors Physiology 030232 urology & nephrology Renal function Angiotensin-Converting Enzyme Inhibitors 030204 cardiovascular system & hematology Gastroenterology Angiotensin Receptor Antagonists 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Physiology (medical) Internal medicine medicine Humans Prospective Studies Prospective cohort study Glucocorticoids Survival rate Serum Albumin Creatinine Proteinuria Glomerulosclerosis Focal Segmental Primary Focal Segmental Glomerulosclerosis business.industry Remission Induction Middle Aged Survival Rate chemistry Moderate proteinuria Drug Therapy Combination Female medicine.symptom business Follow-Up Studies Glomerular Filtration Rate |
| Zdroj: | Clinical and Experimental Nephrology. 22:1315-1323 |
| ISSN: | 1437-7799 1342-1751 |
| Popis: | To compare the efficacy of glucocorticoids in primary focal segmental glomerulosclerosis (pFSGS) patients with moderate proteinuria. Registered at http://www.chictr.org.cn/ , study No. ChiCTR-OPN-17012789. pFSGS patients with urine protein between 1.0 and 3.5 g/24 h were recruited from 2006 to 2016. No decline in urine protein > 50% was observed after 2 months of run-in angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers (ACEI/ARB) treatment. Patients were assigned to study group (glucocorticoids with ACEI/ARB) or control group (ACEI/ARB without glucocorticoids). Variables including 24-h urinary protein, serum albumin and serum creatinine during the trial were recorded. Remission was defined as proteinuria 50%, and our composite end point as > 30% decrease of eGFR or eGFR |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink